84
49
Growth Score
-3 pts
Heat Score
-16 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
2866417
A Novel Psoriasis Therapy
Ilya Budik: CEO
About the Company
Ullman Medical has identified and developed a novel botanical extract which demonstrated positive human clinical data in treating psoriasis and pre-clinical evidence of non-toxic, anti-angiogenesis properties important in the treatment of eye diseases, arthritis, and certain cancers. The company’s objective is the commercialization of this
plant-based compound for the topical treatment of psoriasis and development of a therapeutic platform for the treatment of numerous immune-deficient diseases. Psoriasis remains a chronic skin disease limited to ineffective topical treatments or dangerous, and sometimes deadly class-I steroids and oral immune-suppressants.
